KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2025)

Ginkgo Bioworks Holdings' EBITDA Margin history spans 6 years, with the latest figure at 242.23% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 773.0% year-over-year to 242.23%; the TTM value through Dec 2025 reached 181.66%, up 6072.0%, while the annual FY2025 figure was 181.66%, 6072.0% up from the prior year.
  • EBITDA Margin reached 242.23% in Q4 2025 per DNA's latest filing, down from 207.05% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 34.37% in Q3 2021 to a low of 1134.55% in Q4 2021.
  • Average EBITDA Margin over 5 years is 348.84%, with a median of 246.1% recorded in 2025.
  • The largest YoY upside for EBITDA Margin was 96382bps in 2022 against a maximum downside of -97853bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 1134.55% in 2021, then skyrocketed by 85bps to 170.73% in 2022, then plummeted by -249bps to 596.49% in 2023, then skyrocketed by 58bps to 249.97% in 2024, then rose by 3bps to 242.23% in 2025.
  • Per Business Quant, the three most recent readings for DNA's EBITDA Margin are 242.23% (Q4 2025), 207.05% (Q3 2025), and 116.52% (Q2 2025).